Public health genomics and personalized prevention: Lessons from the COGS project

Journal of Internal Medicine

Volumn 274, Issue 5, 2013, Pages 451-456

  Pashayan, N ^a   Hall, A ^b   Chowdhury, S ^b   Dent, T ^b   Pharoah, P D P ^c   Burton, H ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PHG FOUNDATION   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Ethical; Legal and social issues; Personalized prevention; Polygenic risk stratification; Public health genomics; Screening

Indexed keywords

ACCESS TO INFORMATION; ALLELE; BREAST CANCER; CANCER DIAGNOSIS; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SCREENING; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; EMPIRICAL RESEARCH; FALSE POSITIVE RESULT; GENETIC RISK; GENETIC VARIABILITY; GENOMICS; GROUPS BY AGE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HIGH RISK POPULATION; HUMAN; INDIVIDUALIZATION; LOW RISK POPULATION; MASS SCREENING; MEDICAL EDUCATION; MEDICAL ETHICS; MULTIFACTORIAL INHERITANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYGENIC RISK STRATIFICATION; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH; PUBLIC HEALTH GENOMICS; PUBLIC HEALTH SERVICE; QUALITY ADJUSTED LIFE YEAR; REVIEW;

ETHICAL; LEGAL AND SOCIAL ISSUES; PERSONALIZED PREVENTION; POLYGENIC RISK STRATIFICATION; PUBLIC HEALTH GENOMICS; SCREENING;

GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENOMICS; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; RISK ASSESSMENT;

EID: 84885741248     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12094     Document Type: Review

References (24)

1. Collaborative Oncological Gene-environment Study. http://www.cogseu.org/ (last accessed on 06-05-2013).
2. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008; 358: 2796-803.
3. Zimmern RL. Genomics and individuals in public health practice: are we luddites or can we meet the challenge? J Public Health (Oxf) 2011; 33: 477-82.
4. Burke W, Khoury MJ, Stewart A, Zimmern RL. The path from genome-based research to population health: development of an international public health genomics network. Genet Med 2006; 8: 451-8.
5. Bellagio Group. Report of an expert workshop held at the Rockefeller Foundation Study. 2005. http://www.phgfoundation.org/search/?q=bellagio+ (last accessed on 04-10-2012).
6. Pashayan N, Duffy SW, Chowdhury S, Dent T, Burton H, Neal DE et al. Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer 2011; 104: 1656-63.
7. Janssens AC, van Duijn CM. Genome-based prediction of common diseases: advances and prospects. Hum Mol Genet 2008; 17: R166-73.
8. Hingorani AD, Shah T, Kumari M, Sofat R, Smeeth L. Translating genomics into improved healthcare. BMJ 2010; 341: c5945.
9. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 2002; 31: 33-6.
10. Gail MH. Discriminatory accuracy from single-nucleotide polymorphisms in models to predict breast cancer risk. J Natl Cancer Inst 2008; 100: 1037-41.
11. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 2013; 45: 353-61.
12. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013; 45: 385-91.
13. Risch N. The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol Biomarkers Prev 2001; 10: 733-41.
14. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I, Lindman H. Breast cancer in young women: poor survival despite intensive treatment. PLoS ONE 2009; 4: e7695.
15. Lin DW, Porter M, Montgomery B. Treatment and survival outcomes in young men diagnosed with prostate cancer: a Population-based Cohort Study. Cancer 2009; 115: 2863-71.
16. Gray JA, Patnick J, Blanks RG. Maximising benefit and minimising harm of screening. BMJ 2008; 336: 480-3.
17. Chowdhury S, Dent T, Pashayan N, Hall A, Lyratzopoulos G, Hallowell N et al. Incorporating genomics into breast and prostate cancer screening: assessing the implications. Genet Med 2013; 15: 423-432.
18. Hall AE, Chowdhury S, Pashayan N, Hallowell N, Pharoah P, Burton H. What ethical and legal principles should guide the genotyping of children as part of a personalised screening programme for common cancer?. J Med Ethics 2013; doi:10.1136/medethics-2012-101079.
19. Dent T, Jbilou J, Rafi I, Segnan N, Tornberg S, Chowdhury S et al. Stratified cancer screening: the practicalities of implementation. Public Health Genomics 2013; 15: 423-432.
20. Tayko PRM, Soponkij U. The power of hexagon as an organization development process. AU-GSB e-J 2011; 4: 8-17.
21. Howell A, Astley S, Warwick J, Stavrinos P, Sahin S, Ingham S et al. Prevention of breast cancer in the context of a national breast screening programme. J Intern Med 2012; 271: 321-30.
22. Biesecker LG. Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project. Genet Med 2012; 14: 393-8.
23. Morrow M, Waters J, Morris E. MRI for breast cancer screening, diagnosis, and treatment. Lancet 2011; 378: 1804-11.
24. Evans DG, Warwick J, Astley SM, Stavrinos P, Sahin S, Ingham S et al. Assessing individual breast cancer risk within the U.K. National Health Service Breast Screening Program: a new paradigm for cancer prevention. Cancer Prev Res (Phila) 2012; 5: 943-51.